Granular cell leiomyosarcoma

Summary

Granular cell leiomyosarcoma (MONDO:0003350) is a disease. A subtype of granular cell cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	granular cell leiomyosarcoma
Mondo ID	MONDO:0003350
DOID	DOID:5258
NCIT	C27494
UMLS	C1333871
MedGen	234321
GARD	0023466
Is cancer (heuristic)	no

Also known as: granular cell leiomyosarcoma

Disease family

This is a subtype of granular cell cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › peripheral nervous system disorder › peripheral nervous system neoplasm › nerve sheath neoplasm › granular cell tumor › granular cell cancer › granular cell leiomyosarcoma

Related subtypes (3): malignant gastric granular cell tumor, granular cell carcinoma, malignant cutaneous granular cell skin tumor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.